Transdermal delivery of enfuvirtide using dissolving microneedles integrated with novel insertion and removal indicator


Por: Li, HH, Vora, L, Li, YC, Pandya, AK, Wang, JW, Luo, YD, Abraham, AM, Ballana, E, Riveira, E, Nevot, M, Houghton, J, Mccarthy, HO and Donnelly, RF

Publicada: 10 sep 2025 Ahead of Print: 1 jun 2025
Resumen:
Enfuvirtide, the first HIV fusion inhibitor, exhibits remarkable antiviral efficacy and a favourable safety profile compared with antiretroviral therapy alone. However, its clinical application is constrained by the necessity for subcutaneous administration and the high incidence of injection site reactions (ISRs) in 98 % of patients. This study seeks to overcome these limitations by developing dissolving microneedle array patches (DMAPs), offering a painless and efficient alternative for enfuvirtide delivery. Two bilayer DMAP designs featuring poly(vinyl pyrrolidone) (PVP) based-hydrophilic and poly(lactic acid) (PLA)-based hydrophobic baseplates were engineered, incorporating a novel PLA-silica baseplate as a colorimetric dissolution indicator for visual feedback on successful patch insertion and timely removal. The DMAPs with embedded indicators exhibited a rapid color change from yellow to green within 3 min of insertion into the rats' dorsal skin. This change was triggered by hydration of the dye crystal violet encapsulated in silica, as interstitial fluid migrated from the needle shafts to the baseplate. A subsequent transition to purple occurred within 2 h due to further dye hydration, indicating complete needle dissolution and successful delivery of enfuvirtide. In vivo studies on Sprague Dawley rats demonstrated that enfuvirtide achieved a Cmax of 1864 +/- 480 ng/mL at 0.5 h with the PLA-silica DMAP, compared to 973 +/- 200 ng/mL at 1 h with the PVP-baseplate DMAP. Both formulations exhibited biocompatibility and safety in vivo, with the PLA-silica DMAP supporting rapid drug release suitable for short-term applications, while the PVP-based DMAP offered potential for long-term use without irritation. These findings underscore DMAPs as a promising alternative to subcutaneous injection of enfuvirtide, capable of reducing ISRs and potentially enhancing patient adherence. Notably, this work introduced an innovative solution for prompt patch removal upon complete drug delivery, effectively addressing dosing inconsistencies and enabling individualised administration, which is crucial for ensuring the reliability and patient acceptability for widespread adoption of this technology.

Filiaciones:
Li, HH:
 Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, North Ireland

Vora, L:
 Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, North Ireland

Li, YC:
 Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, North Ireland

Pandya, AK:
 Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, North Ireland

Wang, JW:
 Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, North Ireland

Luo, YD:
 Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, North Ireland

Abraham, AM:
 Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, North Ireland

:
 IrsiCaixa, AIDS Res Inst, Barcelona 08916, Spain

:
 IrsiCaixa, AIDS Res Inst, Barcelona 08916, Spain

:
 IrsiCaixa, AIDS Res Inst, Barcelona 08916, Spain

Houghton, J:
 Queens Univ, Sch Med Dent & Biomed Sci, Belfast BT9 7BL, North Ireland

Mccarthy, HO:
 Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, North Ireland

Donnelly, RF:
 Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, North Ireland
ISSN: 01683659





Journal of Controlled Release
Editorial
Elsevier BV, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 385 Número:
Páginas: 113954-113954
WOS Id: 001518649500001
ID de PubMed: 40532764
imagen Green Submitted, hybrid

MÉTRICAS